Experience of Using Therapeutic Drug Monitoring to Control the Safety of Vancomycin in Intensive Care Unit Patients with Sepsis
Authors:
- A. B. ProkofievAPA. B. Prokofiev
- S. A. BelkovSBS. A. Belkov
- R. E. KazakovRKR. E. Kazakov
- N. G. BerdnikovaNBN. G. Berdnikova
- T. A. RodinaTRT. A. Rodina
- Е. С. МельниковЕМЕ. С. Мельников
- А. А. ДанькоАДА. А. Данько
- N. E. VoronovaNVN. E. Voronova
- R. Z. VafinaRVR. Z. Vafina
- A. V. ZavtonievAZA. V. Zavtoniev
- D. V. TsygankoDTD. V. Tsyganko
- E. Yu. DemchenkovaEDE. Yu. Demchenkova
Open Access
- 3 July 2022
- journal article
- research article
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 10 (2) , 139-150
Abstract
Vancomycin is prescribed to patients in serious condition with infections caused by Gram-positive microorganisms; however, if the therapeutic plasma concentration of the medicinal product is exceeded, it can have a nephrotoxic effect.The aim of the study was to demonstrate the possibility of using therapeutic drug monitoring (TDM) to reduce the risk of developing nephropathy in intensive care unit patients with sepsis.Materials and methods: the study comprised a retrospective analysis of four clinical cases of patients with sepsis admitted to intensive care units of I.V. Davydovsky City Clinical Hospital in 2021 and treated with vancomycin. TDM of vancomycin plasma levels was performed by reverse-phase high-performance liquid chromatography with mass spectrometric detection.Results: using the four cases of septic patients, the study demonstrated that vancomycin at adequate case-specific doses may result in plasma concentrations beyond the therapeutic range. TDM of vancomycin concentrations helped to prevent further deterioration of renal dysfunction in one septic patient having developed acute kidney injury and to control the achievement of therapeutic vancomycin concentrations or timely adjust the dose to that effect in the other three cases.Conclusions: a timely correction of vancomycin dosing with plasma TDM allows for achieving high antimicrobial efficacy in patients with sepsis and minimising the nephrotoxic effect of the medicinal product. Studies of the feasibility of using TDM as a treatment personalisation tool for patients in serious condition will continue in the future.Keywords
This publication has 23 references indexed in Scilit:
- Empiric guideline-recommended weight-based vancomycin dosing and mortality in methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort studyBMC Infectious Diseases, 2012
- Relationship between Vancomycin Trough Concentrations and Nephrotoxicity: a Prospective Multicenter TrialAntimicrobial Agents and Chemotherapy, 2011
- Nephrotoxicity of vancomycin in patients with methicillin‐resistant Staphylococcus aureus bacteraemiaNephrology, 2011
- Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapyInternational Journal of Antimicrobial Agents, 2011
- Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: A systematic review and meta-analysis*Critical Care Medicine, 2010
- Relationship between Initial Vancomycin Concentration‐Time Profile and Nephrotoxicity among Hospitalized PatientsClinical Infectious Diseases, 2009
- Vancomycin Therapeutic Guidelines: A Summary of Consensus Recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases PharmacistsClinical Infectious Diseases, 2009
- A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumoniaClinical Therapeutics, 2007
- Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parametersAmerican Journal of Health-System Pharmacy, 2006
- Proliferative responses observed following vancomycin treatment in renal proximal tubule epithelial cellsToxicology in Vitro, 2004